Twelve-Month and Five-Year Analyses of Risk Factors for New-Onset Diabetes After Transplantation in a Group of Patients Homogeneous for Immunosuppression

被引:11
作者
Dedinska, L. [1 ,2 ,3 ]
Laca, L. [1 ,2 ,3 ]
Miklusica, M. [1 ,2 ,3 ]
Galajda, P. [3 ,4 ]
Mokan, M. [3 ,4 ]
机构
[1] Univ Hosp Martin, Surg Clin, Martin 03601, Slovakia
[2] Univ Hosp Martin, Transplant Ctr, Martin 03601, Slovakia
[3] Comenius Univ, Jessenius Fac Med, Martin, Slovakia
[4] Univ Hosp Martin, Clin Internal Med 1, Martin 03601, Slovakia
关键词
KIDNEY-TRANSPLANTATION; MELLITUS;
D O I
10.1016/j.transproceed.2015.05.017
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective. In the case of new-onset diabetes after transplantation (NODAT) development, it is suitable to reduce calcineurin inhibitors and corticosteroids. But change of immunosuppression can be counterproductive and can cause development of rejection and leads to further NODAT aggravation. Methods. We retrospectively evaluated risk factors after kidney transplantation. Comparison groups were homogeneous in terms of administered immunosuppression, and individual monitored parameters were not distorted by the immunosuppression administered. Results. In the 12-month analysis we identified these risk factors for NODAT: age at the time of transplantation, 50-59 years (P = .0034); age at the time of transplantation, >= 60 years (P < .0001); positive family anamnesis for diabetes mellitus type 2 (P < .0001); body mass index at the time of transplantation, >= 30 kg/m(2) (P = .0236); prediabetes before transplantation (P < .0009); and proteinuria, >0.15 g/d (P < .0002). In the 5-year analysis, we identified patients who were diagnosed with NODAT after the 1st year. We identified age >= 50 years at the time of transplantation to be an independent risk factors for NODAT. Conclusions. It is advisable to carry out the oral glucose tolerance test even in patients with physiologic levels of fasting glycemia.
引用
收藏
页码:1831 / 1839
页数:9
相关论文
共 21 条
[1]   Steroid sparing in kidney transplantation: Changing paradigms, improving outcomes, and remaining questions [J].
Augustine, Joshua J. ;
Hricik, Donald E. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 1 (05) :1080-1089
[2]   Response to comment on: American Diabetes Association. Standards of medical care in diabetes-2011 (vol 34, pg e54, 2011) [J].
Wysham, C. H. ;
Kirkman, M. S. .
DIABETES CARE, 2011, 34 (08) :1887-1887
[3]  
Davidson J, 2003, TRANSPLANTATION S, V75, pSS3
[4]  
Dedinska I, ANN TRANSPL IN PRESS
[5]   Reduced exposure to calcineurin inhibitors in renal transplantation [J].
Ekberg, Henrik ;
Tedesco-Silva, Helio ;
Demirbas, Alper ;
Vitko, Stefan ;
Nashan, Bjorn ;
Guerkan, Alp ;
Margreiter, Raimund ;
Hugo, Christian ;
Grinyo, Josep M. ;
Frei, Ulrich ;
Vanrenterghem, Yves ;
Daloze, Pierre ;
Halloran, Philip F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (25) :2562-2575
[6]  
Galajda P, 2004, DIABETES OBEZITA, V4, P39
[7]   The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events [J].
Hjelmesæth, J ;
Hartmann, A ;
Leivestad, T ;
Holdaas, H ;
Sagedal, S ;
Olstad, M ;
Jenssen, T .
KIDNEY INTERNATIONAL, 2006, 69 (03) :588-595
[8]   Diabetes mellitus after kidney transplantation:: a French multicentre observational study [J].
Kamar, Nassim ;
Mariat, Christophe ;
Delahousse, Michel ;
Dantal, Jacques ;
Al Najjar, Azmi ;
Cassuto, Elisabeth ;
Lefrancois, Nicole ;
Cointault, Olivier ;
Touchard, Guy ;
Villemain, Florence ;
Di Giambattista, Fabienne ;
Benhamou, Pierre-Yves .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (07) :1986-1993
[9]   Diabetes mellitus after kidney transplantation in the United States [J].
Kasiske, BL ;
Snyder, JJ ;
Gilbertson, D ;
Matas, AJ .
AMERICAN JOURNAL OF TRANSPLANTATION, 2003, 3 (02) :178-185
[10]   New-Onset Diabetes Mellitus in Kidney Transplant Recipients Discharged on Steroid-Free Immunosuppression [J].
Luan, Fu L. ;
Steffick, Diane E. ;
Ojo, Akinlolu O. .
TRANSPLANTATION, 2011, 91 (03) :334-341